Kornimate/medical-research-clean huggingface dataset:
effects of exercise training on respiratory performance in patients with fibrosing interstitial lung diseases

Conditions: Lung Diseases; Interstitial Lung Disease; Fibrosis Lung

Summary: the current study recruited patients with fibrosing interstitial lung diseases (f-ild) whatever was the underlying pathology. the investigators aimed to compare the effects of aerobic exercises for lower limbs (ll) versus upper limbs, lower limbs, and breathing exercises (ulb) on the peak exercise measurements that was measured using cardiopulmonary exercise testing (cpet), dyspnea and health related quality of life assessment in this group of patients.

the investigators conducted a case-control study with a follow up after 6 weeks (short term). all the participants on recruited were evaluated clinically. a high resolution computed tomography (hrct) scan of the chest was performed to confirm the diagnosis of f-ild as well as a spirometry. all the patients were subjected to cardiopulmonary exercise testing (cpet), 6-minute walk test (6-mwt), evaluation of dyspnea using mmrc dyspnea scale, and evaluation of health related quality of life using st. george's respiratory questionnaire (sgrq). the control group were followed up by telephone calls. the intervention groups (ll and ulb) were subjected randomly to aerobic exercise training for 6 weeks. after termination of all the session, the patients were re-evaluated clinically and objectively using cpet, 6-mwt, mmrc and sgrq. also, we evaluated the outcome of the patients (control and intervention groups) as those who died or reported exacerbation of the underlying disease were recorded.

Eligibility criteria:
inclusion criteria: * adult patients aged ≥ 18 years. * fibrosis interstitial lung diseases (f-ilds) diagnosed based on hrct radiological features. * restrictive or mixed pattern in forced spirometry test exclusion criteria: * motor disabilities * cardiovascular diseases (as acute heart failure, unstable angina or recent myocardial infarction) * cognitive impairments * history of cerebrovascular accident * active cancer * life expectancy less than 3 months.
proteomics and orthodontic root resorption

Conditions: Root Resorption; Orthodontic Appliance Complication; Orthodontic Pathological Resorption of External Root; Gingival Diseases; Tooth Plaque; Tooth Diseases

Summary: the majority of previous studies for early detection of orthodontically induced inflammatory root resorption (oiirr) were conducted to assess individual biomarkers which are representative of single biological pathway. to our knowledge, no studies have been employed gingival crevicular fluid (gcf) proteomic analysis to identify potential biomarkers for oiirr. therefore; the aim of this study is to use the advantage of testing a package of biomarkers via doing proteomic analysis of gcf which could help in making a more precise personalize diagnosis and treatments, thereby providing orthodontists additional information that cannot be deduced from clinical parameters.

orthodontic patients with age range (18-years) indicated for bilateral maxillary first premolars extraction as part of their orthodontic treatment using specific fixed orthodontic appliance design with moderate anchorage were recruited for this study. both of these premolars were allocated randomly to a heavy ( 225g) and light (25g) force in a split mouth design with a 1:1 allocation ratio. (gcf) was collected from the gingival sulcus of these teeth before extraction at six time intervals which are baseline, 1 hour, 1 day, 1 week , 2 weeks, 3 weeks and 4 weeks. plaque and gingival indices were recorded for those patients at each timeline. premolars will be extracted after 4weeks to be examined by stereomicroscopy for surface area evaluation of root resorption. proteomic analysis will be carried out on the gcf sample. the proteomic analysis of the collected gcf will be obtained by using matrix-assisted laser desorption ionization/ time-of-flight mass spectrometry (maldi-tof/ms). ms spectra will be used to search human protein sequence data bases for protein identification and the development of "protein print" specific for these biological conditions.

Eligibility criteria:
inclusion criteria: * orthodontic patients indicated for extraction of bilateral upper first premolars, * general healthy fit, * good oral hygiene with periodontal health maintenance (plaque index and gingival index ≤1), * lack of radiographic signs of idiopathic resorption, * radiographically both experimental teeth have two roots with approximately equal length and shape, * the position of experimental teeth within the arch with no rotation. exclusion criteria: * patients with impaction except impacted third molars for referral to do cbct, * smokers, * patients on anti-inflammatory drugs at least three months before and during the study, * history of oral habit, * previous orthodontic treatment, * history of dental trauma, * previous dental treatment of the experimental teeth, * patient with heavy occlusion, * pathological lesion in the upper arch.

Keywords: proteomic orthodontic root resorption gingival crevicular fluid
a study of eras-0015 in patients with advanced or metastatic solid tumors

Conditions: Metastatic Solid Tumors

Summary: the main purpose of the study is to assess whether the study drug, eras-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain ras mutations. eras-0015 will be given alone or in combination with other treatments.

this is a first-in-human, phase 1/1b, open-label, multicenter clinical study of eras-0015 as a monotherapy and in combination with other cancer therapies. the study will commence with dose optimization of eras-0015 monotherapy, followed by dose optimization of eras-0015 in combination with other cancer therapies.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * willing and able to give written informed consent * pathological documentation of tumor type and mutation prior to the first dose of study drug(s), for applicable cohorts. * there is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy * able to swallow oral medication * have eastern cooperative oncology group performance status (ecog ps) of 0 or 1 * adequate cardiovascular, hematological, liver, and renal function * willing to comply with all protocol-required visits, assessments, and procedures exclusion criteria: * previous treatment with a ras inhibitor * is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of eras-0015 * received prior palliative radiation within 14 days of cycle 1, day 1 * have primary central nervous system (cns) tumors * prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption * have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the investigator, would compromise study administration as per protocol or compromise the assessment of aes * are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial

Keywords: solid tumor advanced solid tumor solid malignancies targeted therapy molecular alterations pembrolizumab keytruda panitumumab vectibix metastatic solid tumor neoplasms
impact of neuropsychological alteration of decision-making abilities on the functioning of patients with eating disorders

Conditions: Eating Disorder

Summary: eating disorders are multifactorial disorders currently conceptualized in a biopsychosocial model, but pathophysiology remains relatively unknown, and robust etiological models to guide treatment are therefore lacking. different endophenotypes and neurocognitive vulnerability factors have been found in eating disorders including decision making abnormalities. the investigators hypothesize that decision making abnormalities are associated with a lower level of functioning and quality of life which could lead to social and interpersonal difficulties. the investigators also hypothesize that these anomalies are associated with a particular clinical profile (more restrictive profile, more hyperactivity, less insight on the disease and desire for care ...).

the investigators will recruit a total of 340 patients with an eating disorder in the university hospital of montpellier. * participation consists of a one-day visit with a multidisciplinary assessment. no action is specific to research. this is the usual management of patients with eating disorders addressed to our department. * an ancillary study will be proposed, if the patient is addressed by his general practitioner for an annual evaluation. this second visit will be exactly the same as the initial visit.

Eligibility criteria:
inclusion criteria: * patient with an eating disorder according to diagnostic and statistical manuel of mental disorders-v (dsm-v) criteria * patient aged from 15 to 65 years * patient who performs the day-hospital evaluation * patient affiliated to a french social security system * patient able to understand the nature, the aim and the methodology of the study * for minor one of the legal guardians gave his consent exclusion criteria: * patient in an unstable somatic state (eg severe metabolic disorder making impossible or unreliable neuropsychological assessments) * patient's refusal to participate * patient on protective measures (guardianship or trusteeship) * pregnant or nursing women. a dosage of beta human chorionic gonadotropin (βhcg) will be performed to ensure the absence of pregnancy.

Keywords: anorexia nervosa bulimia binge eating disorders neuropsychology neurocognition daily functioning
errors of refraction among primary school children

Conditions: Error, Refractive

Summary: this study will include primary school children to evalute their refraction and follow those who will wear glasses to detect their compliance. visual acuity will be measured using autorefractometer after cycloplegic eye drops 3 times and glasses will be prescribed for those who are needed. follow up of the students to detect their compliance of wearing correction.


Eligibility criteria:
inclusion criteria: * primary school student less than 12 years. * no sensory defect in those children. exclusion criteria: * corneal opacity. * abnormal fundus lesion.
dynamic of immunocompetent populations in patients treated with extracorporeal photopheresis in chronic graft versus host disease

Conditions: Graft Versus Host Disease; Extracorporeal Photopheresis

Summary: extracorporeal photopheresis (ecp) is a cellular therapy indicated in the treatment of chronic gvhd (cgvhd). in this study protocol, patients suffering from inaugural cgvhd will be treated with the association of ecp and corticosteroid treatment. treatment will start by an induction stage with 2 sessions of ecp per week until the 10th week followed by a maintenance stage including one session every other week until the 22th week. the objective of this study is to highlight the immunological mechanism of extracorporeal photopheresis treatment. indeed, ecp is based on an immunomodulatory immunological effect and despite several hypotheses highlighted by different teams; clear mechanisms still need to be defined. this french multicenter study realize an immunological follow-up before and during treatment to elucidate the impact of ecp on immune system of responder patient.


Eligibility criteria:
inclusion criteria: * patients aged ≥18 years who had a first allo-csh for hematological pathology * body weight ≥ 40 kg. * confirmed diagnosis of inaugural cgvhd requiring systemic treatment. * any source of hematopoietic stem cells is allowed. * all conditioning treatments are allowed. * patient validated by the local investigator as eligible for treatment with ecp according to the criteria of the investigating centers * patient treated according to the study plan with a ecp in 2 steps * patient having signed informed consent. * prophylaxis of gvh maintained during the onset of cgvhd is accepted. * effective contraception for men and women of childbearing age. exclusion criteria: * cgvhd ≥ 2nd line of treatment * exclusive pulmonary cgvhd * cgvhd before j100 * cgvhd occurring after donor lymphocyte injection (dli) * overlaps syndrome agvhd-cgvhd * late agvhd * relapsed patient or progressive disease * non-controlled infection * second allograft * leukopenia \<0.5g / l at screening

Keywords: graft versus host disease extracorporeal photopheresis immunomodulatory
empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure

Conditions: Acute Decompensated Heart Failure

Summary: national, multicenter, randomized, double-blind, parallel-group, stratified by sglt-2 inhibitor type, placebo-controlled trial, - a phase iii study. primary objective of the study is to investigate the impact of sglt-2 inhibitors (empagliflozin and dapagliflozin) on clinical endpoints in patients hospitalized with acute/decompensated hf.


Eligibility criteria:
inclusion criteria: * patients 18 years of age with the capacity to provide written informed consent * currently hospitalized for a primary diagnosis of acute/decompensated hf (hfref, hfmref,hfpef), including symptoms and signs of fluid overload regardless of ejection fraction or diabetes status * in patients with hfpef the diagnosis has to be confirmed according to the current hfpef definition (by non-invasive testing: evidence of structural or functional changes in the heart as evidenced on echocardiography or by invasive testing as lvedp assessment or right heart catheterisation). * randomized no earlier than 24 hours and up to 10 days after initial presentation while still hospitalized * stable as defined by: systolic blood pressure (sbp\>100 mmhg for the preceding 6 hours) * no intensification of iv diuretics within the last 6 hours, * no use of iv vasodilators within the last 6 hours, * no use of iv inotropes or levosimendan within the last 24 hours prior to randomization * elevated nt-probnp \>600 pg/ml during the current hospitalization in patients with hfref and \>300 pg/ml in patients with hfmref or hfpef (or above 900 pg/ml if atrial fibrillation is present at admission independently from ef). * egfr \>20 ml/min/1,73m2 exclusion criteria: * history of ketoacidosis * type 1 diabetes * sglt-2 inhibitor at baseline or known allergy to sglt-2 inhibitors * current active cancer with less than 2 years of life expectancy * pulmonary embolism, cerebrovascular accident as the primary trigger for the current hospitalization * cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive cardiomyopathy or known pericardial constriction * any severe (obstructive or regurgitant) valvular heart disease, expected to lead to surgery during the trial period * women of child-bearing potential, defined as all women physiologically capable of becoming pregnant * blood ph\<7.32 * \>1 episode of severe hypoglycaemia within the last 6 months under treatment with insulin or sulfonylurea * acute symptomatic urinary tract infection or genital infection

Keywords: sglt-2 inhibitors dapagliflozin empagliflozin acute heart failure decompensated heart failure
nonlinear elasticity mapping of breast masses

Conditions: Breast Cancer

Summary: this proposed technique, called "nonlinear elasticity mapping (nem)", is an innovative approach to estimate (i.e., linear and nonlinear) elasticity to provide complementary and relevant information for identification and characterization of breast masses. the proposed technique includes imaging the (nonlinear) elasticity parameter in a quantitative manner and measuring two new and relevant parameters. these parameters, together with linear elasticity, are used to differentiate breast masses. the first parameter is the nonlinearity of the elasticity.

measuring the nonlinearity of elasticity is obtained by recording ultrasound scans of object under different values of externally applied compression, and processing the resulting data. the central element of the proposed method is the solution of an inverse problem by which the linear and nonlinear parameters are estimated and a map of tissue nonlinearity is produced, in which the malignant masses can be identified. in addition to estimating the elasticity, will also evaluate the heterogeneity of the (linear) elasticity parameter distribution within the mass as an indicator of malignancy. in a previously performed pilot study, tested the proposed method on a small group of patients. the goal of this project is to take the next logical step, which is to test this method in a clinical study on a larger population of patients to obtain statistically meaningful results. assuming that the proposed method continues to demonstrate high specificity, this technique can have a significant impact on breast cancer diagnosis and management.

Eligibility criteria:
inclusion criteria: * without a history of mastectomy or implants, which are identified to have findings on their clinical breast ultrasound. exclusion criteria: * previous mastectomy or implants * any condition that does not allow proper use of imaging devices.

Keywords: breast mass
mechanism of action of galiximab in subjects with previously untreated follicular non-hodgkin's lymphoma

Conditions: Lymphoma, Non-Hodgkin's

Summary: the purpose of the study is to evaluate the mechanism(s) of action of galiximab in subjects with previously untreated follicular nhl.


Eligibility criteria:
inclusion criteria: * written informed consent (signed and dated). * age equal or greater than 18 at the time of consent. * histologically confirmed follicular nhl according to the revised european american lymphoma (real)/ world health organization (who) classification (from initial diagnosis) grades 1,2, or 3a. * at least 2 malignant lymph nodes of similar size (\>1 cm in minimal dimension) and location that are readily accessible for excisional biopsy at the time of study entry. * consent to 1 pretreatment and 1 post-treatment excisional biopsy of accessible tumor. * acceptable hematologic, hepatic, and renal function parameters. * who performance status equal or less than 2. * subjects of reproductive potential must agree to follow accepted birth control methods. exclusion criteria: * presence of lymphoma in cns. * previous systemic anticancer treatment for nhl (including but not limited to radiation, myeloablative, or investigational therapy). * concurrent treatment with systemic steroids within 14 days of day 1. * evidence of transformed lymphoma. * presence of malignancies within 3 years of study day 1 (except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (dcis) of breast, or basal or squamous cell skin cancer). * history of hiv infection or aids. * serious nonmalignant disease. * pregnant. * inability to comply with study and follow-up procedures. * any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug.

Keywords: galiximab untreated nhl antibody open-label
oral anticoagulant apixaban for treatment of venous thromboembolism

Conditions: Venous Thromboembolism

Summary: patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.


Eligibility criteria:
inclusion criteria: * children and adolescents with a newly diagnosed primary vte. * treatment with apixaban has to begin within 72 hours of the diagnosis of vte. * patients who have received heparin at the beginning of their diagnosis and are willing to switch to apixaban, are allowed to do so within 72 hours of their treatment. patients who are switched to apixaban are not allowed to receive any other systemic anticoagulant therapy. * vte confirmed by diagnostic imaging. * children with body weight of ≥ 40 kg and are able to tolerate medication by mouth or administered via an ng or gt tube. * adequate liver function: ast and/or alt \<5 times uln, and/or direct bilirubin \<2 times uln * platelet count of at least ≥ 30,000/ul. * adequate renal function: \>30% of gfr for age * female subjects of childbearing potential must not be nursing or pregnant with negative urine pregnancy test within 72 hours prior to dosing with study medication. * signed written informed consent exclusion criteria: * current or recent (within 3 months) apixaban administration. * patient is unable to tolerate medications by oral route or by n/g administration, peptic ulcer disease, intestinal obstruction, toxic megacolon, typhlitis, or short gut syndrome. * history of primary bleeding disorder and first degree family history of bleeding disorder. * active bleeding or high risk of bleeding at the time of study entry. * history of significant head injury and/or any history of intracranial hemorrhage. * conditions predispose to intracranial bleed; e.g. brain tumor, brain metastasis. * uncontrolled grade 3 or 4 severe hypertension. * history of allergy to apixaban or factor xa inhibitors.
study evaluating renal cell carcinoma risk factors

Conditions: Carcinoma, Renal Cell

Summary: this is an epidemiological, prospective, multicenter study designed to identify the pre-treatment clinical, molecular and genetic prognostic factors associated with progression free survival in patients naïve to renal cell carcinoma (rcc) treatment.

invitation to volunteer

Eligibility criteria:
inclusion criteria: * treatment naïve patients with proven advanced rcc will be evaluated. (except surgery or radiotherapy) * =18 years, any gender. * patients with advanced renal cell carcinoma and treatment naïve. exclusion criteria: * patients who have already initiated any kind of specific therapy for the treatment of rcc.2. * patients with other neoplasias different from rcc (current or past).
remifentanil and propofol versus fentanyl and midazolam for sedation during therapeutic hypothermia. a randomised, controlled trial

Conditions: Hypothermia

Summary: the aim of this study is to increase knowledge about drug properties and effects during therapeutic hypothermia. the primary end point of this study is the time from termination of sedation to extubation in patients treated with therapeutic hypothermia, after treatment with the combination remifentanil and propofol versus that of fentanyl and midazolam.


Eligibility criteria:
inclusion criteria: * treatment with therapeutic hypothermia following cardiac arrest (33-34°c) and analgesia/sedation required * patients must be 18 years or older * inclusion must be approved by the attending physician exclusion criteria: * pregnant women * cardiovascular unstable patients in a deteriorating circulatory status which require multiple other therapeutic measures that makes participation practically impossible * liver or renal failure defined as sequential organ failure assessment (sofa)-score 3 or 4 * history of drug allergies, or contraindications for the study drugs * patients using a scheduled dose of any of the study drugs. * patients with a known substance abuse of opioids or benzodiazepines

Keywords: therapeutic hypothermia cardiac arrest sedation remifentanil propofol fentanyl midazolam